Nachi Palaniappan

Velindre Cancer Centre

Papers

1

Total Citations

18

H-Index

1

About

Dr. Nachi Palaniappan is a leading clinical researcher in head and neck oncology, with a focused expertise in de-escalation strategies for human papillomavirus (HPV)-positive oropharyngeal cancer. Her major contribution is advancing risk-stratified, reduced-intensity treatment protocols designed to preserve excellent survival outcomes while minimizing the severe, long-term toxicities associated with conventional therapies. She is the principal investigator of the landmark PATHOS trial (Phase II/III), a practice-shaping study that investigates tailoring adjuvant treatment intensity after transoral surgery based on pathological risk features. This work, cited 18 times, addresses the critical need to improve quality of life for the growing population of younger, healthier HPV-positive patients. Dr. Palaniappan’s research directly challenges the one-size-fits-all paradigm, aiming to spare patients from unnecessary chemotherapy and radiation toxicity without compromising cure rates. Her contributions are pivotal in the ongoing shift toward personalized, function-preserving care in head and neck cancer, making her a key voice in defining the future standard of treatment for this disease.

Research Focus

Key Achievements

1
H-Index
1
Papers
18
Total Citations
18
Avg Citations/Paper
🏆 Most Cited Paper
PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer.
18 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Velindre Cancer Centre

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago